Under construction – not a live service
Sign in
Taking people in United KingdomNo phase

Looks back at outcomes of acalabrutinib in chronic lymphocytic leukaemia patients in the UK

Reviews records of UK leukaemia patients who started acalabrutinib through an early access programme.

Plain-language title generated from the registry record
Registry title: Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

Key facts

Where
Aylesbury, Bath, Birmingham, Bournemouth, Cardiff, Cornwall, Dartford, Derby, Doncaster, Dorset, Eastbourne, Hull, Leicester, Lincoln, Liverpool, London, Mid Yorkshire, Middlesbrough, Newcastle, North Shields, Norwich, Nottingham, Oxford, Plymouth, Southampton, Stockton-on-Tees, Stoke-on-Trent, and Wigan, United KingdomSee the 28 sites

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic lymphocytic leukaemia who had no earlier treatment. They started acalabrutinib through the UK Early Access Programme.

Age
18 years or older
Sex
All sexes can join
Disease stage
Chronic lymphocytic leukaemia (CLL). People later found to have small lymphocytic lymphoma (SLL) may also be included.
Earlier treatment
No earlier treatment for CLL. They started acalabrutinib through the UK Early Access Programme, with the first dose between 1 April 2020 and 1 April 2021.

Read by machine on 9 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 130 years old?

Source: NCT05557695, who can take part

Where in United Kingdom

  • AylesburyHospital not named in the registryTaking people
  • BathHospital not named in the registryTaking people
  • BirminghamHospital not named in the registryTaking people
  • BournemouthHospital not named in the registryTaking people
  • CardiffHospital not named in the registryTaking people
  • CornwallHospital not named in the registryTaking people
  • DartfordHospital not named in the registryTaking people
  • DerbyHospital not named in the registryTaking people
  • DoncasterHospital not named in the registryTaking people
  • DorsetHospital not named in the registryTaking people
  • EastbourneHospital not named in the registryTaking people
  • HullHospital not named in the registryTaking people
  • LeicesterHospital not named in the registryTaking people
  • LincolnHospital not named in the registryTaking people
  • LiverpoolHospital not named in the registryTaking people
  • LondonHospital not named in the registryTaking people
  • Mid YorkshireHospital not named in the registryTaking people
  • MiddlesbroughHospital not named in the registryTaking people
  • NewcastleHospital not named in the registryTaking people
  • North ShieldsHospital not named in the registryTaking people
  • NorwichHospital not named in the registryTaking people
  • NottinghamHospital not named in the registryTaking people
  • OxfordHospital not named in the registryTaking people
  • PlymouthHospital not named in the registryTaking people
  • SouthamptonHospital not named in the registryTaking people
  • Stockton-on-TeesHospital not named in the registryTaking people
  • Stoke-on-TrentHospital not named in the registryTaking people
  • WiganHospital not named in the registryTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
AstraZeneca
Trial code
NCT05557695
Record updated
9 September 2026
Original description
This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study). Physicians treating chronic lymphocytic leukaemia patients with acalabrutinib, where the patients started treatment as part of the acalabrutinib Early Access Programme (EAP), will be invited to recruit patients. Clinical data will be extracted from the patients' clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients who were started on acalabrutinib as part of the UK acalabrutinib EAP.Read full original descriptionShow less

A Non-interventional, Observational Cohort Study of Chronic Lymphocytic Leukaemia Patients Treated With Acalabrutinib in the First-line Setting Through the UK Early Access Programme: Early Access Programme Outcomes In aCalabrutinib (EPIC).

This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study). Physicians treating chronic lymphocytic leukaemia patients with acalabrutinib, where the patients started treatment as part of the acalabrutinib Early Access Programme (EAP), will be invited to recruit patients. Clinical data will be extracted from the patients' clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients who were started on acalabrutinib as part of the UK acalabrutinib EAP.

Exclusion: None listed in study protocol.

The study population will include treatment-naïve patients with chronic lymphocytic lymphoma (CLL)* who meet the following inclusion criteria:; Treatment-naïve CLL patients who were initiated on acalabrutinib as part of the UK Early Access Programme; Received their first dose of acalabrutinib between 1 April 2020 and 1 April 2021; Patients aged ≥18 years old; Note: patients later found to have small lymphocytic lymphoma (SLL) may also be included in the EAP.

ClinicalTrials.gov NCT05557695